Smoker

More Than Fast: Jackery Set to Unveil New Flagship Product at IFA 2022

Retrieved on: 
Monday, August 15, 2022 - 2:00pm

FREMONT, Calif., Aug. 15, 2022 /PRNewswire/ -- Leading solar power technology solution provider, Jackery , has released plans to unveil a new flagship product at IFA 2022 in August in Berlin.

Key Points: 
  • FREMONT, Calif., Aug. 15, 2022 /PRNewswire/ -- Leading solar power technology solution provider, Jackery , has released plans to unveil a new flagship product at IFA 2022 in August in Berlin.
  • The incoming Solar Generator 1000 Pro is a testament to the brand's commitment to technical innovation and design and will serve as a flagship product moving forward.
  • Jackery will be celebrating the launch of its new flagship product from 15:00 - 16:00 on August 31st at Hall 3.2 Booth 111.
  • The all-new Solar Generator 1000 Pro from Jackery features a range of upgrades from the very popular Jackery Solar Generator 1000.

Seventy Percent (70%) of Patients Surveyed Voice Concern About Tobacco Corporations’ Ownership of Lung Disease Treatments

Retrieved on: 
Monday, August 15, 2022 - 1:20pm

The survey gave people with chronic lung disease a voice in the conversation about tobacco corporations owning companies that develop tools and medications to treat lung conditions.

Key Points: 
  • The survey gave people with chronic lung disease a voice in the conversation about tobacco corporations owning companies that develop tools and medications to treat lung conditions.
  • Based on the surveys findings, as reported in Thorax, most patients care deeply that tobacco companies have a financial stake in drug or device companies and profit from life-saving treatment.
  • Vectura develops several widely used medical delivery devices and/or formulations for inhaled therapies used in people with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
  • It is morally wrong,
    They made lots of money; they should research and develop treatments for those that used their products.

Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

Retrieved on: 
Thursday, August 11, 2022 - 9:05pm

SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2022 financial results and provided an update on the cytisinicline clinical development program.

Key Points: 
  • SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2022 financial results and provided an update on the cytisinicline clinical development program.
  • In April, Achieve announced positive, statistically significant results in its Phase 3 ORCA-2 clinical trial of cytisinicline in 810 adult smokers across 17 clinical trial locations in the United States.
  • Also in June, following the NIH grant award, Achieve initiated the ORCA-V1 clinical trial across five trial locations in the United States.
  • Total operating expenses for the three and six months ended June 30, 2022 were $10.1 million and $17.3 million, respectively.

Weber Inc. Lawsuit Alert: Kaplan Fox & Kilshiemer LLP Notifies Weber Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Wednesday, August 10, 2022 - 3:56pm

NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Weber Inc. (Weber or Company) (NYSE: WEBR).

Key Points: 
  • NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Weber Inc. (Weber or Company) (NYSE: WEBR).
  • Weber is an outdoor cooking company that sells grills, smokers, grilling accessories, and solid fuel products across the world.
  • On or around August 6, 2021, Weber conducted its IPO by selling over 17.8 million shares of Class A common stock at $14.00 per share.
  • With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.

LUNGevity to Present Three Research Abstracts at 2022 World Lung Conference

Retrieved on: 
Tuesday, August 9, 2022 - 1:00pm

WASHINGTON, Aug. 9, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to report that three of our Patient-Focused Research Center (Patient FoRCe) studies have been selected to be presented at the 2022 World Conference on Lung Cancer (WCLC) to be held August 6-9, 2022, in Vienna, Austria.  

Key Points: 
  • WASHINGTON, Aug. 9, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to report that three of our Patient-Focused Research Center (Patient FoRCe) studies have been selected to be presented at the 2022 World Conference on Lung Cancer (WCLC) to be held August 6-9, 2022, in Vienna, Austria.
  • Lung cancer healthcare providers work hard to deliver quality care to patients but are one piece of the puzzle.
  • The three abstracts presented at WCLC 2022 reiterate the importance of integrating the patient and caregiver perspective in both clinical research and healthcare delivery.
  • LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer.

WEBER INC. (NYSE: WEBR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Weber Inc. (NYSE: WEBR)

Retrieved on: 
Monday, August 8, 2022 - 9:00pm

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired the Class A common stock of Weber Inc. (“Weber” or the “Company”) (NYSE: WEBR) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s August 2021 initial public offering (“IPO” or the “Offering”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1933.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1933.
  • Weber is an outdoor cooking company that sells grills, smokers, grilling accessories, and solid fuel products across the world.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Weber Inc. to Announce Fiscal Third Quarter 2022 Results on August 15, 2022

Retrieved on: 
Monday, August 8, 2022 - 3:00pm

Weber Inc. (Weber) (NYSE: WEBR), the global leader in outdoor cooking innovation, technology, and products, today announced that it plans to release its fiscal third quarter 2022 financial results on Monday, August 15, 2022.

Key Points: 
  • Weber Inc. (Weber) (NYSE: WEBR), the global leader in outdoor cooking innovation, technology, and products, today announced that it plans to release its fiscal third quarter 2022 financial results on Monday, August 15, 2022.
  • Weber management will host a conference call at 7:30 a.m. CT that morning to discuss its financial results.
  • Investors and analysts are invited to dial 833-927-1758 (international callers, please dial 929-526-1599) approximately 10 minutes before the start of the call.
  • A live webcast of the conference call and supporting materials will be available on the Weber investor relations website, https://investors.weber.com .

United Kingdom-based Smoking Cessation program Reports that 30 percent of Support in a Lung Cancer Screening Program: The Yorkshire Enhanced Stop Smoking Study (YESS)

Retrieved on: 
Monday, August 8, 2022 - 9:30am

VIENNA, Aug. 8, 2022 /PRNewswire-PRWeb/ -- Patients with lung cancer who attended a lung cancer screening event and who then participated in a personalized smoking cessation study achieved smoking abstinence rates of more than 30 percent, according to research presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

Key Points: 
  • Many participants who undergo lung cancer screening continue to smoke and while screening offers a teachable moment for smoking cessation, there is little data to demonstrate what approach to smoking cessation is most effective.
  • To test the effectiveness of a personalized approach, United Kingdom-based researchers developed the Yorkshire Enhanced Stop Smoking (YESS) trial, which offered stop smoking support on an opt-out basis to all eligible smokers attending a lung health check event, which included low-dose CT screening.
  • During a lung health check event, 2150 people who reported a history of smoking were offered the opportunity to see a smoking cessation professional.
  • For more information, visit https://wclc2022.iaslc.org/
    Chris Martin, The International Association for the Study of Lung Cancer, 6306702745, cmartin@davidjamesgroup.com

INVESTOR DEADLINE: Investors in Weber Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – WEBR

Retrieved on: 
Saturday, August 6, 2022 - 4:58am

22-cv-03966 (N.D. Ill.), the Weber class action lawsuit charges Weber, certain of its top executives and directors, and the IPOs underwriters with violations of the Securities Act of 1933.

Key Points: 
  • 22-cv-03966 (N.D. Ill.), the Weber class action lawsuit charges Weber, certain of its top executives and directors, and the IPOs underwriters with violations of the Securities Act of 1933.
  • A lead plaintiff acts on behalf of all other class members in directing the Weber class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Weber class action lawsuit.
  • An investors ability to share in any potential future recovery of the Weber class action lawsuit is not dependent upon serving as lead plaintiff.

ALLEN CARR'S EASYWAY TO STOP SMOKING LIVE GROUP SEMINARS, THE INNOVATIVE BRITISH DRUG-FREE QUIT SMOKING PROGRAMME, RECEIVES APPROVAL FROM NICE

Retrieved on: 
Friday, August 5, 2022 - 12:01am

NICE found that the Allen Carr's Easyway Live Group Seminars were not only cost-effective but cost-saving when compared to existing treatments and that the evidence proving the effectiveness of the method is comparable to that which exists for 'nicotine e-cigarettes' which maintain the addiction.

Key Points: 
  • NICE found that the Allen Carr's Easyway Live Group Seminars were not only cost-effective but cost-saving when compared to existing treatments and that the evidence proving the effectiveness of the method is comparable to that which exists for 'nicotine e-cigarettes' which maintain the addiction.
  • The Easyway live seminars, which can be taken "in the room" or via Zoom, comprise of a live presentation of the method delivered by a former smoker who used the method to quit themselves.
  • Once that flawed belief system is fully understood, smokers can actually enjoy the process of getting free from smoking.
  • These updated NICE guidelines should encourage health care providers to adopt Allen Carr's Easyway to Stop Smoking Live Group Seminars as an effective option for those quitting smoking."